Results 81 to 90 of about 61,341 (287)

Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease [PDF]

, 2017
Capillary electrophoresis coupled with mass spectrometry (CE-MS) has been used as a platform for discovery and validation of urinary peptides associated with chronic kidney disease (CKD).
Mischak, Harald, Pontillo, Claudia
core   +1 more source

Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT

European Journal of Heart Failure, 2020
Spironolactone up‐titration may be limited by side effects that could be minimized at lower than target doses, but whether lower than target doses remain efficacious is unknown.
J. Ferreira, X. Rosselló, S. Pocock, P. Rossignol, B. Claggett, J. Rouleau, S. Solomon, B. Pitt, M. Pfeffer, F. Zannad   +9 more
semanticscholar   +1 more source

Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides

ESC Heart Failure, Volume 12, Issue 2, Page 879-887, April 2025.
Abstract Background Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF). Aims This study aimed to characterize patients with exertional dyspnoea and normal/near‐to‐normal N‐terminal pro‐brain natriuretic peptide (NT ...
Emmanuelle Berthelot, Tarek Laouar, Antoine Beurnier, Nataliya Hrynchynshyn, Jean Christophe Eicher, Jean‐Michel Tartière, Patrick Jourdain, Olivier Lairez, Barnabas Gellen   +8 more
wiley   +1 more source

Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis

BMC Cardiovascular Disorders
Background Eplerenone and spironolactone, recognized as mineralocorticoid receptor antagonists (MRAs), have been reported to improve clinical prognosis among individuals diagnosed with heart failure (HF).
Ahmed Elshahat, Ahmed Mansour, Mohamed Ellabban, Ahmed Diaa, Atef Hassan, Ahmed Fawzy, Omar Abdulrahman Saad, Moaz Abouelmagd, Mahmoud Eid, Ahmed Elaraby, Mohamed Hamouda Elkasaby, Ahmed Abdelaziz   +11 more
doaj   +1 more source

Novel approach to adherence assessment based on parent drug and metabolite pharmacokinetics: pilot study with spironolactone

Biomedical Papers
Aim. The aim of this study was to evaluate adherence to spironolactone in a group of unselected patients with arterial hypertension by analysis of measured serum spironolactone and canrenone concentrations according to a proposed two-step decision scheme
Alena Pilkova, Martin Sima, Jan Miroslav Hartinger, Thi Minh Phuong Nikrynova Nguyen, Vera Maresova, Ivana Kurcova, Ondrej Slanar, Jiri Widimsky   +7 more
doaj   +1 more source

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk

Frontiers in Pharmacology, 2023
Aims: Few studies have compared the association between dosing of spironolactone and outcomes in patients with heart failure with preserved ejection fraction (HFpEF), and whether spironolactone dose could significantly affect the prognosis of HFpEF ...
Jun-Feng Li, Xiang Qu, Zhan Gao, Chang-Xi Chen, Feng-Yu Zhang, Ling Cheng, Xi Zhou, Hao Zhou   +7 more
doaj   +1 more source

Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis

European Journal of Heart Failure, 2020
It is unclear whether spironolactone reduced heart failure (HF) hospitalizations in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial through potential diuretic or other effects.
A. Kalogeropoulos, Jincy Thankachen, J. Butler, J. Fang   +3 more
semanticscholar   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials

Clinical and Experimental Hypertension, 2017
This study was designed to assess the effect of additional spironolactone on blood pressure in patients with resistant hypertension. MEDLINE, EMBASE, and Cochrane Library were searched to identify randomized controlled trials (RCTs) that determined the ...
Liping Liu, Bing Xu, Yunfeng Ju
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source